A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Trial Profile

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs DNX 2401 (Primary) ; Interferon gamma
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms TARGET-I
  • Sponsors DNAtrix
  • Most Recent Events

    • 06 Jun 2017 Results (n=27) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2017 According to a DNAtrix media release, data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
    • 24 Apr 2017 According to a DNAtrix media release, results from this trial will be presented at the Annual Meeting of the American Association of Neurological Surgeons (AANS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top